Traditional cancer drug development relies on cell lines and animal models that often fail to accurately mimic human tumor biology, leading to ineffective therapies and high clinical trial failure rates. The lack of predictive preclinical models hinders the development of personalized cancer treatments tailored to individual patient needs.

Danwang Medical provides a comprehensive organoid biobank and associated services for creating custom cancer models that more closely recapitulate human tumor microenvironments. Their platform enables pharmaceutical companies and research institutions to conduct more accurate drug screening, toxicology evaluations, and personalized medicine research. By using patient-derived organoids, Danwang Medical aims to improve the efficiency and success rate of cancer drug development, and facilitate the development of targeted therapies based on individual tumor characteristics. The company also offers D1med organoid chips for advanced in-vitro studies.

Extensive biobank of patient-derived organoids representing various cancer types, including prostate, ovarian, endometrial, breast, kidney, bile duct, pancreatic, lung, gastric, and intestinal cancers.

Custom organoid model development services tailored to specific research needs.

Human tumor organoid and normal organoid reagents for cell culture and experimentation.

D1med organoid chips, including open and closed vascularized options, for advanced microenvironment studies.

Services for compound screening, immune co-culture, and toxicology evaluation using human-derived organoids.

Pathological analysis platform for detailed characterization of organoid models.

Automated equipment to support high-throughput organoid culture and analysis.

Danwang Medical primarily serves pharmaceutical companies, research institutions, and hospitals involved in cancer drug discovery, preclinical research, and personalized medicine development.